WO2022083603A1 - 半胱氨酸蛋白酶抑制剂与Cathepsin复合物作为肿瘤诊断标志物的应用 - Google Patents
半胱氨酸蛋白酶抑制剂与Cathepsin复合物作为肿瘤诊断标志物的应用 Download PDFInfo
- Publication number
- WO2022083603A1 WO2022083603A1 PCT/CN2021/124817 CN2021124817W WO2022083603A1 WO 2022083603 A1 WO2022083603 A1 WO 2022083603A1 CN 2021124817 W CN2021124817 W CN 2021124817W WO 2022083603 A1 WO2022083603 A1 WO 2022083603A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cathepsin
- cystatin
- cancer
- complex
- quantitative detection
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 42
- 102000005600 Cathepsins Human genes 0.000 title claims abstract description 37
- 108010084457 Cathepsins Proteins 0.000 title claims abstract description 37
- 101000749287 Clitocybe nebularis Clitocypin Proteins 0.000 title claims abstract description 17
- 101000767029 Clitocybe nebularis Clitocypin-1 Proteins 0.000 title claims abstract description 17
- 229940094664 Cysteine protease inhibitor Drugs 0.000 title claims abstract description 17
- 239000003550 marker Substances 0.000 title abstract description 11
- 238000003745 diagnosis Methods 0.000 claims abstract description 23
- 238000004458 analytical method Methods 0.000 claims abstract description 14
- 238000004393 prognosis Methods 0.000 claims abstract description 7
- 238000001514 detection method Methods 0.000 claims description 48
- 239000003795 chemical substances by application Substances 0.000 claims description 27
- 102000015833 Cystatin Human genes 0.000 claims description 24
- 108050004038 cystatin Proteins 0.000 claims description 24
- 102000018968 Salivary Cystatins Human genes 0.000 claims description 20
- 108010026774 Salivary Cystatins Proteins 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 18
- 239000000523 sample Substances 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 10
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 9
- 206010017758 gastric cancer Diseases 0.000 claims description 9
- 201000011549 stomach cancer Diseases 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 7
- 201000010881 cervical cancer Diseases 0.000 claims description 7
- 201000004101 esophageal cancer Diseases 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 7
- 108010061641 Cystatin A Proteins 0.000 claims description 6
- 102100031237 Cystatin-A Human genes 0.000 claims description 6
- 238000002965 ELISA Methods 0.000 claims description 6
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 6
- 201000002313 intestinal cancer Diseases 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 239000007790 solid phase Substances 0.000 claims description 6
- 201000002510 thyroid cancer Diseases 0.000 claims description 6
- 108090000712 Cathepsin B Proteins 0.000 claims description 5
- 102000004225 Cathepsin B Human genes 0.000 claims description 5
- 108090000619 Cathepsin H Proteins 0.000 claims description 5
- 102000004175 Cathepsin H Human genes 0.000 claims description 5
- 108090000625 Cathepsin K Proteins 0.000 claims description 5
- 102000004171 Cathepsin K Human genes 0.000 claims description 5
- 108090000624 Cathepsin L Proteins 0.000 claims description 5
- 102000004172 Cathepsin L Human genes 0.000 claims description 5
- 108090000613 Cathepsin S Proteins 0.000 claims description 5
- 102100035654 Cathepsin S Human genes 0.000 claims description 5
- 108010061635 Cystatin B Proteins 0.000 claims description 5
- 108010061642 Cystatin C Proteins 0.000 claims description 5
- 102000012177 Cystatin M Human genes 0.000 claims description 5
- 108010061617 Cystatin M Proteins 0.000 claims description 5
- 102100026891 Cystatin-B Human genes 0.000 claims description 5
- 102100026897 Cystatin-C Human genes 0.000 claims description 5
- 102100028182 Cystatin-D Human genes 0.000 claims description 5
- 102100028188 Cystatin-F Human genes 0.000 claims description 5
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 claims description 5
- 101000916687 Homo sapiens Cystatin-D Proteins 0.000 claims description 5
- 101000916688 Homo sapiens Cystatin-F Proteins 0.000 claims description 5
- 230000000903 blocking effect Effects 0.000 claims description 5
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 claims description 5
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 claims description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 5
- 239000011534 wash buffer Substances 0.000 claims description 5
- 238000000749 co-immunoprecipitation Methods 0.000 claims description 4
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 3
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 230000004927 fusion Effects 0.000 claims description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 2
- 238000011490 co-immunoprecipitation assay Methods 0.000 claims description 2
- 239000002852 cysteine proteinase inhibitor Substances 0.000 claims 1
- 239000003547 immunosorbent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 238000011088 calibration curve Methods 0.000 description 8
- 102000005927 Cysteine Proteases Human genes 0.000 description 6
- 108010005843 Cysteine Proteases Proteins 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000004020 luminiscence type Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 206010064390 Tumour invasion Diseases 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000009400 cancer invasion Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000000594 atomic force spectroscopy Methods 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012916 chromogenic reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229940124272 protein stabilizer Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000005641 tunneling Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96466—Cysteine endopeptidases (3.4.22)
Abstract
Description
Claims (23)
- 半胱氨酸蛋白酶抑制剂与Cathepsin复合物的定量检测剂在制备用于肿瘤的诊断、辅助诊断或预后分析的试剂盒中的应用;所述半胱氨酸蛋白酶抑制剂选自Cystatin A、Cystatin B、Cystatin C、Cystatin D、Cystatin E、Cystatin F、Cystatin S、Cystatin SA以及Cystatin SN(CST1)中的任一种;所述Cathepsin选自Cathepsin B、Cathepsin H、Cathepsin K、Cathepsin L以及Cathepsin S中的任一种。
- 根据权利要求1所述的应用,其中,所述半胱氨酸蛋白酶抑制剂与Cathepsin复合物选自CST1-Cathepsin L以及CST1-Cathepsin B。
- 根据权利要求1所述的应用,其中,所述肿瘤选自肺癌、肝癌、胃癌、食管癌、肠癌、前列腺癌、宫颈癌、乳腺癌和甲状腺癌中的一种。
- 根据权利要求1所述的应用,其中,所述定量检测剂为所述半胱氨酸蛋白酶抑制剂以及所述Cathepsin的特异性抗体,所述抗体可用于执行免疫共沉淀或酶联免疫吸附试验以对所述半胱氨酸蛋白酶抑制剂与Cathepsin复合物进行检测。
- 根据权利要求1所述的应用,其中,所述定量检测剂为所述半胱氨酸蛋白酶抑制剂与Cathepsin复合物的特异性抗体。
- 根据权利要求4或5所述的应用,其中,所述特异性抗体具有用于指示信号强度的标记。
- 根据权利要求6所述的应用,其中,所述用于指示信号强度的标记选自发色团、地高辛标记探针、电子致密物质、胶体金或酶中的任一种或多种。
- 一种用于肿瘤诊断、辅助诊断或预后分析的半胱氨酸蛋白酶抑制剂与 Cathepsin复合物的定量检测剂;其中,所述半胱氨酸蛋白酶抑制剂选自Cystatin A、Cystatin B、Cystatin C、Cystatin D、Cystatin E、Cystatin F、Cystatin S、Cystatin SA以及Cystatin SN(CST1)中的任一种;所述Cathepsin选自Cathepsin B、Cathepsin H、Cathepsin K、Cathepsin L以及Cathepsin S中的任一种。
- 根据权利要求8所述的定量检测剂,其中,所述半胱氨酸蛋白酶抑制剂与Cathepsin复合物选自CST1-Cathepsin L以及CST1-Cathepsin B。
- 根据权利要求8所述的定量检测剂,其特征在于,所述肿瘤选自肺癌、肝癌、胃癌、食管癌、肠癌、前列腺癌、宫颈癌、乳腺癌和甲状腺癌中的一种。
- 根据权利要求8所述的定量检测剂,其特征在于,所述定量检测剂为所述半胱氨酸蛋白酶抑制剂以及所述Cathepsin的特异性抗体,所述抗体可用于执行免疫共沉淀或酶联免疫吸附试验以对所述半胱氨酸蛋白酶抑制剂与Cathepsin复合物进行检测。
- 根据权利要求8所述的定量检测剂,其中,所述定量检测剂为所述半胱氨酸蛋白酶抑制剂与Cathepsin复合物的特异性抗体。
- 根据权利要求11或12所述的定量检测剂,其中,所述特异性抗体具有用于指示信号强度的标记。
- 根据权利要求13所述的定量检测剂,其中,所述用于指示信号强度的标记选自发色团、地高辛标记探针、电子致密物质、胶体金或酶中的任一种或多种。
- 肿瘤诊断、辅助诊断或预后分析试剂盒,,所述试剂盒包含权利要求4或5任一项中所定义的特异性抗体。
- 根据权利要求15所述的试剂盒,其中,还包含固相载体、封闭液、显色剂、半胱氨酸蛋白酶抑制剂与Cathepsin融合抗原的校准品以及洗涤缓冲液中的至少一种。
- 根据权利要求16所述的试剂盒,其中,所述固相载体为化学发光板。
- 一种肿瘤的诊断、辅助诊断或预后分析的方法,所述方法包括:使用根据权利要求8所述的定量检测剂或根据权利要求15所述的试剂盒测量样本中半胱氨酸蛋白酶抑制剂与Cathepsin复合物的含量。
- 根据权利要求18所述的方法,其中,所述肿瘤选自肺癌、肝癌、胃癌、食管癌、肠癌、前列腺癌、宫颈癌、乳腺癌和甲状腺癌中的一种。
- 根据权利要求18所述的方法,其中,所述定量检测剂为所述半胱氨酸蛋白酶抑制剂以及所述Cathepsin的特异性抗体,所述抗体可用于执行免疫共沉淀或酶联免疫吸附试验以对所述半胱氨酸蛋白酶抑制剂与Cathepsin复合物进行检测。
- 根据权利要求18所述的方法,其中,所述定量检测剂为所述半胱氨酸蛋白酶抑制剂与Cathepsin复合物的特异性抗体。
- 根据权利要求20或21所述的方法,其中,所述特异性抗体具有用于指示信号强度的标记。
- 根据权利要求22所述的方法,其中,所述用于指示信号强度的标记选自发色团、地高辛标记探针、电子致密物质、胶体金或酶中的任一种或多种。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011135626.5 | 2020-10-22 | ||
CN202011135626.5A CN112379093B (zh) | 2020-10-22 | 2020-10-22 | CST-Cathepsin复合物作为肿瘤诊断标志物的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022083603A1 true WO2022083603A1 (zh) | 2022-04-28 |
Family
ID=74580546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/124817 WO2022083603A1 (zh) | 2020-10-22 | 2021-10-20 | 半胱氨酸蛋白酶抑制剂与Cathepsin复合物作为肿瘤诊断标志物的应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN112379093B (zh) |
WO (1) | WO2022083603A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115806623A (zh) * | 2023-01-05 | 2023-03-17 | 广州达魏科技有限公司 | 一种Cathepsin L抑制组合物在细胞扩增中的用途 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112379097B (zh) * | 2020-10-22 | 2022-07-26 | 上海良润生物医药科技有限公司 | Cst1-ctsb复合物作为结肠直肠癌诊断标志物的应用 |
CN112379094B (zh) * | 2020-10-22 | 2022-07-26 | 上海良润生物医药科技有限公司 | Cst1-ctsh复合物作为食管癌诊断标志物的应用 |
CN112379093B (zh) * | 2020-10-22 | 2023-06-16 | 上海良润生物医药科技有限公司 | CST-Cathepsin复合物作为肿瘤诊断标志物的应用 |
CN112014578B (zh) * | 2020-10-22 | 2021-01-22 | 上海良润生物医药科技有限公司 | 半胱氨酸蛋白酶抑制剂SN与Cathepsin L1复合物作为胃癌诊断标志物的应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107367615A (zh) * | 2016-05-11 | 2017-11-21 | 优势医疗有限责任公司 | 检测癌症的方法和试剂盒 |
CN112014578A (zh) * | 2020-10-22 | 2020-12-01 | 上海良润生物医药科技有限公司 | 半胱氨酸蛋白酶抑制剂SN与Cathepsin L1复合物作为胃癌诊断标志物的应用 |
CN112379097A (zh) * | 2020-10-22 | 2021-02-19 | 上海良润生物医药科技有限公司 | Cst1-ctsb复合物作为结肠直肠癌诊断标志物的应用 |
CN112379094A (zh) * | 2020-10-22 | 2021-02-19 | 上海良润生物医药科技有限公司 | Cst1-ctsh复合物作为食管癌诊断标志物的应用 |
CN112379093A (zh) * | 2020-10-22 | 2021-02-19 | 上海良润生物医药科技有限公司 | CST-Cathepsin复合物作为肿瘤诊断标志物的应用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE77700T1 (de) * | 1986-03-10 | 1992-07-15 | Imre Corp | Immunkomplextestverfahren. |
AU7457996A (en) * | 1995-10-20 | 1997-05-07 | Dana-Farber Cancer Institute | Cystatin m, a novel cysteine proteinase inhibitor |
FI980647A0 (fi) * | 1998-03-23 | 1998-03-23 | Aboatech Ltd | Nytt foerfarande foer diagnostisering av sjukdomar, foer staellande och uteslutande av en differentialdiagnos |
US7171311B2 (en) * | 2001-06-18 | 2007-01-30 | Rosetta Inpharmatics Llc | Methods of assigning treatment to breast cancer patients |
DE602006018578D1 (de) * | 2005-01-28 | 2011-01-13 | Childrens Medical Center | Diagnose- und prognoseverfahren von blasenkrebs. |
US20070218519A1 (en) * | 2005-10-11 | 2007-09-20 | Tethys Bioscience, Inc. | Diabetes-associated markers and methods of use thereof |
CN101598731B (zh) * | 2009-05-07 | 2013-04-24 | 陈志南 | 一种用于肿瘤病理诊断用途的免疫组织化学诊断试剂盒 |
CN101985651B (zh) * | 2010-04-30 | 2013-09-25 | 苏州工业园区为真生物医药科技有限公司 | 胃肠肿瘤诊断和预示的新分子标记 |
EP2577315B1 (en) * | 2010-06-03 | 2017-04-12 | Idexx Laboratories, Inc. | Markers for renal disease |
JP6192123B2 (ja) * | 2012-01-09 | 2017-09-06 | スージョウ マイクロダイアグ バイオメディスン カンパニー リミテッド | 乳癌の予測および診断のためのバイオマーカー |
JP6138154B2 (ja) * | 2012-01-09 | 2017-05-31 | スージョウ マイクロダイアグ バイオメディスン カンパニー リミテッド | 乳癌の予測および診断のためのバイオマーカー |
CN103911426B (zh) * | 2013-05-07 | 2016-04-27 | 上海良润生物医药科技有限公司 | 半胱氨酸蛋白酶抑制剂s的应用 |
CN103940996B (zh) * | 2013-05-07 | 2016-03-16 | 上海良润生物医药科技有限公司 | Cystatin SN和AFP在制备诊断和预示肝癌标志物中的应用 |
CN103941016B (zh) * | 2013-05-07 | 2016-04-27 | 上海良润生物医药科技有限公司 | 半胱氨酸蛋白酶抑制剂sn与癌胚抗原的联合应用 |
CN103898205B (zh) * | 2013-05-07 | 2016-04-27 | 上海良润生物医药科技有限公司 | 半胱氨酸蛋白酶抑制剂sn的应用 |
KR101583397B1 (ko) * | 2013-08-22 | 2016-01-07 | 고려대학교 산학협력단 | 인플루엔자 바이러스 a 감염 여부 판별용 키트 |
CN107033240B (zh) * | 2016-02-04 | 2021-01-15 | 中国疾病预防控制中心寄生虫病预防控制所 | 一种棘球蚴病诊断抗原及其应用 |
CN107688095A (zh) * | 2017-08-19 | 2018-02-13 | 杭州飞悦生物技术有限公司 | 检测人胱抑素sn的酶联免疫试剂盒及制备方法及检测方法 |
US20210223234A1 (en) * | 2018-06-01 | 2021-07-22 | Colgate-Palmolive Company | Methods, Devices and Systems for Quantifying Biomarkers |
CN110031616B (zh) * | 2019-04-03 | 2020-07-28 | 浙江众意生物科技有限公司 | 一种辅助诊断疾病的检测试剂盒 |
CN111388651B (zh) * | 2020-05-09 | 2022-05-03 | 山东大学齐鲁医院 | Cst-14在制备骨质疏松症治疗药物中的应用 |
-
2020
- 2020-10-22 CN CN202011135626.5A patent/CN112379093B/zh active Active
-
2021
- 2021-10-20 WO PCT/CN2021/124817 patent/WO2022083603A1/zh active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107367615A (zh) * | 2016-05-11 | 2017-11-21 | 优势医疗有限责任公司 | 检测癌症的方法和试剂盒 |
CN112014578A (zh) * | 2020-10-22 | 2020-12-01 | 上海良润生物医药科技有限公司 | 半胱氨酸蛋白酶抑制剂SN与Cathepsin L1复合物作为胃癌诊断标志物的应用 |
CN112379097A (zh) * | 2020-10-22 | 2021-02-19 | 上海良润生物医药科技有限公司 | Cst1-ctsb复合物作为结肠直肠癌诊断标志物的应用 |
CN112379094A (zh) * | 2020-10-22 | 2021-02-19 | 上海良润生物医药科技有限公司 | Cst1-ctsh复合物作为食管癌诊断标志物的应用 |
CN112379093A (zh) * | 2020-10-22 | 2021-02-19 | 上海良润生物医药科技有限公司 | CST-Cathepsin复合物作为肿瘤诊断标志物的应用 |
Non-Patent Citations (2)
Title |
---|
KOS J ET AL: "Cysteine proteinases and their inhibitors in extracellular fluids: Markers for diagnosis and prognosis in cancer.", INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS., WICHTIG EDITORE, MILAN., IT, vol. 15, no. 1, 1 January 2000 (2000-01-01), IT , pages 84 - 89, XP002220071, ISSN: 0393-6155 * |
ZORE I, ET AL.: "CATHEPSIN B/CYSTATIN C COMPLEX LEVELS IN SERA FROM PATIENTS WITH LUNG AND COLORECTAL CANCER", BIOLOGICAL CHEMISTRY, WALTER DE GRUYTER GMBH & CO., BERLIN, DE, vol. 382, no. 05, 1 May 2001 (2001-05-01), BERLIN, DE , pages 805 - 810, XP001107112, ISSN: 1431-6730, DOI: 10.1515/BC.2001.097 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115806623A (zh) * | 2023-01-05 | 2023-03-17 | 广州达魏科技有限公司 | 一种Cathepsin L抑制组合物在细胞扩增中的用途 |
CN115806623B (zh) * | 2023-01-05 | 2023-11-21 | 营龄(武汉)生物科技有限公司 | 一种Cathepsin L抑制组合物在细胞扩增中的用途 |
Also Published As
Publication number | Publication date |
---|---|
CN112379093A (zh) | 2021-02-19 |
CN112379093B (zh) | 2023-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022083603A1 (zh) | 半胱氨酸蛋白酶抑制剂与Cathepsin复合物作为肿瘤诊断标志物的应用 | |
US20190154693A1 (en) | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin | |
US20190361028A1 (en) | Free ngal as a biomarker for cancer | |
WO2022083586A1 (zh) | 半胱氨酸蛋白酶抑制剂sn与cathepsin l1复合物作为胃癌诊断标志物的应用 | |
US20110053156A1 (en) | Small cell lung carcinoma biomarker panel | |
WO2022063156A1 (zh) | 乳腺癌的生物标志物及其应用 | |
EP3657174B1 (en) | Use of laminin 2 for diagnosing hepatocellular carcinoma and pancreatic cancer | |
WO2022083582A1 (zh) | 半胱氨酸蛋白酶抑制剂SN与Cathepsin B复合物作为结肠直肠癌诊断标志物的应用 | |
WO2022083580A1 (zh) | 半胱氨酸蛋白酶抑制剂SN与Cathepsin H复合物作为食管癌诊断标志物的应用 | |
US20070117100A1 (en) | Biomarker for determining predisposition and/or prognosis of hepatocellular carcinoma | |
US20220236275A1 (en) | Cancer test method | |
Tejerina-Miranda et al. | Angiogenesis inhibitor or aggressiveness marker? The function of endostatin in cancer through electrochemical biosensing | |
KR101130842B1 (ko) | 폐암 진단용 Xage-1d 마커 및 이를 이용한 진단 키트 | |
WO2021246153A1 (ja) | 膵臓がんの検出方法及び検出試薬 | |
CA2702623A1 (en) | Use of tenascin-w as a biomarker for colon cancer | |
JP2012103142A (ja) | 筋萎縮性側索硬化症マーカー及びその利用 | |
WO2024047283A1 (en) | Methods for detection of prostate cancer, related biomarkers and kits for determining the biomarkers | |
KR101652894B1 (ko) | 대장암에 대한 신규 바이오마커 및 그의 용도 | |
CA2852757A1 (en) | Predictive biomarkers for breast cancer | |
WO2017060840A1 (en) | Use of htra1 for early detection of colorectal cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21882018 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21882018 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21882018 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC |